Microchimerism and scleroderma: An update

被引：11

作者：

Carol M. Artlett

机构：

[1] Division of Rheumatology, Department of Medicine, Thomas Jefferson University, 233 South 10th Street, Philadelphia, 19107, PA

来源：

Current Rheumatology Reports | 2003年 / 5卷 / 2期

关键词：

Graft Versus Host Disease; Human Leukocyte Antigen; Human Leukocyte Antigen Class; Scleroderma; Systemic Sclerosis;

D O I：

10.1007/s11926-003-0044-2

中图分类号：

学科分类号：

摘要：

Microchimerism has been defined by the presence of a low number of circulating cells transferred from one individual to another. This transfer takes place naturally during pregnancy, between mother and fetus, or between fetuses in multigestational pregnancies. Furthermore, the establishment of microchimerism can also occur during blood transfusion, as well as during bone marrow and solid-organ transplants. Recently, microchimeric cells have been implicated in the pathogenesis of autoimmune diseases, particularly systemic sclerosis. Studies have demonstrated an increased presence of microchimeric cells in peripheral blood and tissues from patients with systemic sclerosis, and, more recently, microchimeric cells were demonstrated to be specifically activated and capable of recognizing patient human leukocyte antigens. © 2003, Current Science Inc.

引用

页码：154 / 159

页数：5

共 39 条

[1]

Artlett C.M., Smith J.B., Jimenez S.A., Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis, N Eng J Med, 338, pp. 1186-1191, (1998)

[2]

Artlett C.M., Cox L.A., Ramos R.C., Et al., Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosis, Clin Immunol, 103, pp. 303-308, (2002)

[3]

Artlett C.M., Welsh K.I., Black C.M., Jimenez S.A., Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis, Immunogenetics, 47, pp. 17-22, (1997)

[4]

Nelson J.L., Furst D.E., Maloney S., Et al., Microchimerism and HLA-compatible relationships of pregnancy in scleroderma, Lancet, 351, pp. 559-562, (1998)

[5]

Artlett C.M., Microchimerism in health and disease, Curr Molec Med, 2, pp. 525-535, (2002)

[6]

Artlett C.M., Smith J.B., Jimenez S.A., New perspectives on the etiology of systemic sclerosis, Molec Med Today, 5, pp. 74-78, (1999)

[7]

McCormick L.L., Zhang Y., Tootell E., Gilliam A.C., Anti-TGF-b treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma, J Immunol, 163, pp. 5693-5699, (1999)

[8]

Zhang Y., McCormick L.L., Desai S.R., Et al., Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation, J Immunol, 168, pp. 3088-3098, (2002)

[9]

Evans P.C., Lambert N., Maloney S., Et al., Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma, Blood, 93, pp. 2033-2037, (1999)

[10]

Lambert N.C., Evans P.C., Hashizumi T.L., Et al., Persistent fetal microchimerism in T lymphocytes is associated with HLADQA1* 0501: implications in autoimmunity, J Immunol, 164, pp. 5545-5548, (2000)

← 1 2 3 4 →